Tag Archives: SRPT

Sarepta Therapeutics: Backing A Cure For Duchenne Muscular Dystrophy

Succeeding 13 years of R&D with a commercial-level rare disease drug, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) tees up to deliver on the latter half of its promise to provide the world with a DMD cure for sufferers that may be amenable to Exon 51 skipping, and otherwise. A result that would facilitate the first cure for DMD and sizable growth potential.

In 2016, Sarepta Therapeutics,....More>>>

Mid-Afternoon Market Update: Crude Oil Up Over 1%; Sarepta Shares Jump After Positive Results In DMD

Toward the end of trading Wednesday, the Dow traded up 0.42 percent to 21,845.34 while the NASDAQ climbed 0.41 percent to 6,401.95. The S&P also rose, gaining 0.42 percent to 2,468.27.

Leading and Lagging Sectors

Wednesday afternoon, the energy shares surged 1.23 percent. Meanwhile, top gainers in the sector included Frontline Ltd. (NYSE: FRO), up 5 percent, and JA....More>>>

Top 10 High Tech Stocks To Invest In 2018

“Mors tua, vita mea” (literally “your death is my life) probably was the motto that gladiators, in the ancient Rome, recited before entering in the Coliseum and fighting for their life. Over and above its literal translation, this Latin expression means that what is a damage for one person is often an advantage for another. There can only be one winner in a competition; that is....More>>>

stock analyst

Click to enlarge

Quick Take

Electronics manufacturer Microphase (Pending:MPHSE) has filed an amended S-1 registration statement with notable new details.

The company experienced a severe drop in revenues and in gross margin in Q3 2016 due to a combination of factors within its control and outside its control.

Microphase has not yet provided an expected price range for....More>>>

Best Energy Stocks To Invest In Right Now

What happened

Shares of Southwestern Energy (NYSE:SWN) fell sharply on Friday, and were down more than 11% by 3:00 p.m. EST. Fueling today’s sell-off was the company’s fourth-quarter results and 2017 guidance.

So what

On the one hand, Southwestern Energy’s fourth-quarter results marked quite a turnaround for the company. That’s after it reported adjusted....More>>>

Top Low Price Stocks To Watch Right Now

EMM & QNX will be the growth drivers going forward. But the risks in BlackBerry stock continue to remain elevated.

BlackBerry(NSDQ:BBRY)stock is a very volatile stock. When the company announced its latest set of earnings on the 20th of December, the share price rose to around $8 a share, but since then has plummeted back down to the $7 level. Blackberry is unique in that it is a low....More>>>

Why Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today”

Overall, stocks did well on Monday, and the Dow climbed 90 points even as other major benchmarks posted similar or slightly larger percentage gains. Market participants seemed to be heartened by President Trump’s performance on the first overseas visit of his administration over the weekend, and most investors were content to wait for clearer gauges of whether the U.S. economy is....More>>>

Top 10 Value Stocks To Own For 2017

The travails and triumphs of the market visited two of its mavens this week, when a PR fiasco sunk Warren Buffett (Trades, Portfolio) stock United Airlines and an unlikely burst occurred in one of Prem Watsa (Trades, Portfolio)’s most stubborn stocks, BlackBerry.

Shares of United Continental Holdings dropped 4.29% on Monday and Tuesday, shaving $88.9 million off of Buffett’s holding....More>>>

investment manager

Steven Mnuchin could soon be signing your money, so it’s kind of a big deal that his signature is illegible.

President-elect Trump has picked Mnuchin to replace Jack Lew as the next Treasury secretary. If the Senate approves his Cabinet pick, then Mnuchin’s signature will appear in the lower right corner of newly printed currency.

But he’s no John Hancock. Mnuchin’s....More>>>

Biotech Stocks: ‘Help Me M&A, You’re My Only Hope’

Biotech stocks are having a great day today–iShares Nasdaq Biotechnology ETF (IBB) has climbed 2.5% to $276.92–leading some to suggest that 2017 could be better for investors than 2016 was. Not Baird’s Brian Skorney and Michael Ulz, who “don’t think 2017 will be worse than 2016″ but “aren’t quite sure it will be much better.” They explain....More>>>